Chan Liana C, Basuino Li, Diep Binh, Hamilton Stephanie, Chatterjee Som S, Chambers Henry F
Division of Infectious Disease, Department of Medicine, San Francisco General Hospital, San Francisco, California, USA Division of Molecular Medicine, Harbor-UCLA Medical Center, Torrance, California, USA
Division of Infectious Disease, Department of Medicine, San Francisco General Hospital, San Francisco, California, USA.
Antimicrob Agents Chemother. 2015 May;59(5):2960-3. doi: 10.1128/AAC.05004-14. Epub 2015 Mar 9.
The role of mecA mutations in conferring resistance to ceftobiprole and ceftaroline, cephalosporins with anti-methicillin-resistant Staphylococcus aureus (MRSA) activity, was determined with MRSA strains COL and SF8300. The SF8300 ceftaroline-passaged mutant carried a single mecA mutation, E447K (E-to-K change at position 447), and expressed low-level resistance. This mutation in COL conferred high-level resistance to ceftobiprole but only low-level resistance to ceftaroline. The COL ceftaroline-passaged mutant, which expressed high-level resistance to ceftobiprole and ceftaroline, had mutations in pbp2, pbp4, and gdpP but not mecA.
利用耐甲氧西林金黄色葡萄球菌（MRSA）菌株COL和SF8300，确定了mecA突变在赋予对头孢比普和头孢洛林（具有抗MRSA活性的头孢菌素）耐药性方面的作用。经头孢洛林传代的SF8300突变体携带单个mecA突变，即E447K（第447位发生E到K的变化），并表现出低水平耐药性。COL中的这种突变赋予对头孢比普的高水平耐药性，但仅对头孢洛林表现出低水平耐药性。对头孢比普和头孢洛林均表现出高水平耐药性的COL头孢洛林传代突变体在pbp2、pbp4和gdpP中存在突变，但mecA未发生突变。
